Figure 3. Effects of empagliflozin versus placebo on first and recurrent gout events in subgroups.

Total (first and recurrent) self-reported episodes of gout recorded as adverse events (serious or non-serious) analysed using the Andersen-Gill extension of Cox regression with adjustment for the covariates used in the minimisation algorithm (categories of age, sex, diabetes, estimated glomerular filtration rate, urinary albumin-to-creatinine ratio and region). n/N represents total number of events / number of participants and rate is expressed as total events per 1000 patient-years. Reasons for missing uric acid: analyses were not conducted in participants from China (n=986) or participants who did not provide additional optional consent for long-term sample storage for biochemical analysis. *To convert uric acid to mg/dL, divide by 59.48 (380 μmol/L ≈ 6.4 mg/dL; 470 μmol/L ≈ 7.9 mg/dL).^†Trend test excludes missing category. Uric-acid lowering therapy includes xanthine oxidase inhibitors and primary uricosuric drugs (see Methods). GFR = glomerular filtration rate.